Aktis Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKTS research report →
Range $35 – $40
Price Chart
About the company
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes.
- CEO
- Matthew Roden
- IPO
- 2026
- Employees
- 79
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on AKTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.28B
- P/E
- -22.86
- PEG
- -0.23
- P/S
- 151.13
- P/B
- 2.74
- EV/EBITDA
- -20.13
- Div Yield
- 0.00%
- Gross Margin
- 81.95%
- Op Margin
- -813.35%
- Net Margin
- -679.25%
- ROE
- -32.35%
- ROIC
- -13.09%
Latest fiscal year · YoY change
- Revenue
- $6.50M+336.9%
- Gross Profit
- $6.50M+336.9%
- Op Income
- $-74,684,000
- Net Income
- $-63,731,000-44.9%
- EPS
- $-1.19+5.6%
- OCF Growth
- -534.4%
- FCF Growth
- -719.4%
- 52W High
- $34.19
- 52W Low
- $14.72
- 50D MA
- $24.99
- 200D MA
- $21.15
- Beta
- 0.45
- RSI (14)
- 48
- Avg Volume
- 365.09K
No earnings-call transcripts are available for AKTS yet.
- Free Float
- 0.9%
- Shares Outstanding
- 53.40M
- Float Shares
- 483.13K
of shares held by institutions
69 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bioimpact Capital LLC | 4.84M | 0 |
| Ecor1 Capital, LLC | 4.82M | 0 |
| Blue Owl Capital Holdings LP | 3.07M | ▼ 91.13K |
| Blackrock, Inc. | 2.28M | ▲ 166.23K |
| T. Rowe Price Investment Management, Inc. | 2.05M | ▼ 72.36K |
| Wellington Management Group Llp | 1.97M | ▼ 350.80K |
| Rtw Investments, LP | 1.59M | 0 |
| Janus Henderson Group PLC | 1.45M | ▲ 1.45M |
| Ra Capital Management, L.P. | 1.31M | ▼ 188.68K |
| Baker Bros. Advisors LP | 996.35K | 0 |
| Octagon Capital Advisors LP | 960.85K | 0 |
| Merck & Co., Inc. | 952.84K | 0 |
Held by 107 ETFs
Biggest fund positions in AKTS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 12, 26 | ELI LILLY & Co | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AKTS coverage
Recent articles, reports, and earnings notes.
No research on AKTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AKTS report →Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks
investopedia.com · Aug 14
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
globenewswire.com · Aug 13
Aktis Oncology: Mini-Proteins With A Targeted Punch
seekingalpha.com · Jun 11
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
globenewswire.com · May 27
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
globenewswire.com · May 21
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
fool.com · May 13
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
globenewswire.com · May 11
Aktis Oncology to Present at the BofA Securities Health Care Conference
globenewswire.com · May 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.